Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1993-08-23
1996-02-27
Lovering, Richard D.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 181, 252644, 252645, 252646, A61K 5100, C09K 1104
Patent
active
054946549
DESCRIPTION:
BRIEF SUMMARY
Radiolytic self-decomposition of radiochemicals has always been a problem to manufacturers and users alike. Shelf-life can be as little as a few weeks despite the use of the most suitable storage temperatures and physical dispersal methods for each particular, compound or isotope. The subject is discussed in Review 16, Self-decomposition of Radiochemicals, Amersham International plc, Amersham.
Generally applicable additives which could be added to radiochemicals in Order to extend shelf-life and improve efficiency by minimising the formation of radioactive impurities, would be of great economic and scientific value. A user of a stabilised radiochemical would benefit from being able to conduct experiments over a longer time span,-achieve more consistent results between batches of the same radiochemical, and use less rigorous storage conditions. The additive should minimally interfere with or be compatible with the processes occurring in the application of radiochemicals to experimental systems, such as protein or nucleic acid manipulation.
U.S. Pat. No. 4,390,517 teaches the use of a wide range of soluble primary, secondary and tertiary amines as stabilisers for radiolabelled compounds.
U.S. Pat. No. 4,411,881 teaches the use of thiocarbonylated amines as stabilisers.
U.S. Pat. No. 4,451,451 teaches the use of 4-aminobenzoic acid as an antioxidant in compositions containing Technetium-99m.
U.S. Pat. No. 4,793,987 teaches the use of a range of pyridine carboxylic acids as stabilisers.
32-P radiolabelled nucleotides are often sold as buffered aqueous solutions shipped in dry ice and sold for storage by the customer at -20.degree. C. It would be a significant advantage, both to the shipper and to the customer, if the radiolabelled nucleotides could be supplied at ambient temperature and stored in an unfrozen form.
Solutions of radiolabelled nucleotides and other organic compounds are generally sold colourless. A coloured solution would be an advantage, since it would make the solution more easily visible during manipulation. However, a suitable dye would need not to interfere with any process in which the radiolabelled organic chemical might be used.
In one aspect the invention provides a composition comprising an organic compound labelled with a .beta.-emitting radionuclide, said radiolabelled organic compound being subject to radiolytic decomposition during storage and shipment, together with a stabiliser selected from tryptophan, para-aminobenzoate, indoleacetate, luminol, and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another.
In another aspect, the invention provides a composition comprising a solution of an organic compound labelled with a .beta.-emitting radionuclide and a dye.
The invention is mainly concerned with radiolabelled organic compounds which are supplied, shipped and stored in solution, usually aqueous solution or less usually in solution in a hydrophilic organic solvent. The invention also encompasses compositions in the solid state e.g. those produced by lyophilising or otherwise drying liquid compositions. The invention is applicable to radiolabelled organic compounds which are subject to radiolytic self-decomposition, for example: amino acids, steroids, lipids, fatty acids, peptides, carbohydrates, proteins, and particularly nucleotides, thionucleotides, nucleosides and nucleic acids.
The nature of the .beta.-emitting radionuclide is not critical; 3-H and 14-C are possible, but 32-P, 35-S and 33-P are preferred.
The stabiliser is preferably selected from L- and D-tryptophan; para-aminobenzoate which term is used to include the free acid and salts and esters thereof; indoleacetate which term is used to include the free acid and salts and esters thereof; luminol (3-aminophthalhydrazide); and the group of azoles which are compounds having a 5-membered ring with at least two ring nitrogen atoms directly bonded to one another. Such compounds preferably have the structure ##STR1##
which structure contains two ri
REFERENCES:
patent: 3261747 (1966-07-01), Commerford
patent: 3673410 (1972-06-01), Waite et al.
patent: 4095950 (1978-06-01), Kahn
patent: 4390517 (1983-06-01), O'Brien
patent: 4411881 (1983-10-01), Tzodikov
patent: 4451451 (1984-05-01), Rimmer
patent: 4793987 (1988-12-01), Henderson
patent: 4880615 (1989-11-01), Charleson
patent: 4966854 (1990-10-01), Fleming
patent: 5093105 (1992-03-01), Flanagan et al.
patent: 5101020 (1992-03-01), Fleming
patent: 5262175 (1993-11-01), Solanki
Chemical Abstracts, vol. 111, No. 11, 11 Sep. 1989, Columbus, Ohio, US Abstract No. 93463b.
Buckley Elizabeth M.
May Christopher C.
Price Roger M.
Stone Timothy
Amersham International plc
Chapman Lara E.
Lovering Richard D.
LandOfFree
Radiolabelled compound formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabelled compound formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabelled compound formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1676987